Plavix
Brilique gains NICE approval
October 31, 2011Sales and Marketing ACS, Brilique, NICE, Plavix, clopidogrel
AstraZeneca’s Brilique has been approved by NICE for use in combination with aspirin as an option to treat patients with …
Plavix sales plummet in England
May 5, 2011Sales and Marketing BMS, Plavix, Sanofi-Aventis, clopidogrel
GP prescriptions for Plavix saw a significant drop in England last year as doctors opted for cheaper generic forms of …
AZ’s Brilique approved in Europe
December 7, 2010Sales and Marketing AZ, AstraZeneca, Brilique, Plavix, acute coronary syndromes, antiplatelet, atherothrombotic events, ticagrelor
European regulator have approved AstraZeneca’s oral antiplatelet Brilique (ticagrelor tablets). Brilique can now be used for the prevention of atherothrombotic …
Genzyme again snubs suitor Sanofi
November 10, 2010Research and Development, Sales and Marketing Campath, Chris Viehbacher, Genzyme, Henri Termeer, Orphan Drugs, Plavix, Sanofi, Sanofi-Aventis, manufacturing compliance
Genzyme has once again snubbed Sanofi-Aventis as the French pharma firm continues its pursuit of the beleaguered biotech company. Henri …
AstraZeneca’s Brilinta delayed
September 16, 2010Sales and Marketing Brillinta, Effient, Plavix, clopidogrel
AstraZeneca’s blood thinning drug Brilinta faces an extra three month delay to its review by the FDA. The US regulator …
Generic clopidogrel helps NICE recommend blood clot prevention
August 5, 2010Sales and Marketing NICE, Plavix
NICE has given preliminary approval for wider use of Sanofi-Aventis’s Plavix and Boehringer Ingelheim’s Persantine to prevent blood clots. It …
Sanofi under investigation for anti-competitive practices
May 20, 2010Sales and Marketing Plavix, Sanofi
Sanofi-Aventis is to be investigated by the French Competition Authority for anti-competitive practices, following allegations it prevented the launch of …
In search of a real solution to the counterfeit problem
May 10, 2010Manufacturing and Production Plavix, counterfeits, supply chain
For a great deal of the last decade, warnings from the pharmaceutical industry about the growing threat of counterfeit medicines …
Plavix boosts BMS first quarter figures
April 30, 2010Sales and Marketing BMS, Plavix
Plavix has boosted Bristol-Myers Squibb’s performance in the first quarter of the year, with sales of the anti-clotting blockbuster up …
EMA calls for generic clopidogrel recall
March 31, 2010Manufacturing and Production Plavix, clopidogrel
Problems at a manufacturing facility in India have resulted in eight generic version of the antiplatelet agent clopidogrel being recalled …
FDA strengthens Plavix safety warning
March 15, 2010Sales and Marketing Plavix
A boxed warning has been added to the US packaging of Sanofi-Aventis and Bristol-Myers Squibb’s blockbuster anti-clotting drug Plavix. The …
Sanofi’s Plavix combination recommended for European approval
December 21, 2009Research and Development, Sales and Marketing DuoPlavin, Plavix, Sanofi, cabazitaxel, eplivanserin, idrabiotaparinux
Sanofi-Aventis has received the backing of a key European regulatory committee for its cardiology treatment DuoPlavin, which combines its blockbuster …
Plavix to face six generic competitors in Europe
June 17, 2009Sales and Marketing Plavix, Sanofi-Aventis
Plavix is to face competition from six generics in Europe, potentially decimating sales of Sanofi-Aventis' brand in the region. Plavix …
Plavix sales help BMS into profit
January 29, 2009Sales and Marketing BMS, Plavix
Strong fourth quarter sales of its blockbuster blood thinner Plavix have helped Bristol-Myers Squibb back into the black. Net earnings …
Latest content
Five Facts about cardiovascular disease
